The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

All authors are employees of the UnitedHealth Group. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is ...

Myriad Genetics ( ($MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...

The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...